Quarterly report [Sections 13 or 15(d)]

Note 4 - Note Receivable

Note 4 - Note Receivable	3 Months Ended
Mar. 31, 2025
Notes to Financial Statements
Financing Receivables [Text Block]	4. Note receivable During the year ended December 31, 2023, the Company sold its $2,000,000 stock investment in LINICO and recorded an impairment of $1,400,000 and a note receivable of $600,000. The note was payable over a 12-month installment which began in January 2024. The balance of the note receivable was $100,000 as of December 31, 2024, and was fully collected as of March 31, 2025. The Company accounted for the LINICO investment under ASC 321, Investments-Equity Securities, using the measurement alternative of recording at cost as the investment in LINICO did not have a readily determinable fair value.

Note 4 - Note Receivable

3 Months Ended

Mar. 31, 2025

4. Note receivable

During the year ended December 31, 2023, the Company sold its $2,000,000 stock investment in LINICO and recorded an impairment of $1,400,000 and a note receivable of $600,000. The note was payable over a 12-month installment which began in January 2024. The balance of the note receivable was $100,000 as of December 31, 2024, and was fully collected as of March 31, 2025.

The Company accounted for the LINICO investment under ASC 321, Investments-Equity Securities, using the measurement alternative of recording at cost as the investment in LINICO did not have a readily determinable fair value.